Voyager Therapeutics (VYGR) announced the appointment of Nathan Jorgensen, Ph.D., MBA, as Chief Financial Officer, CFO, effective July 8, 2024. Jorgensen brings to Voyager a breadth of experience spanning investment banking, public and private healthcare investing, sell-side research, and operational roles in biotech, as well as expertise in neuroscience. He most recently served as Chief Financial Officer for Vor Biopharma (VOR).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VYGR:
- Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer
- Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s Disease
- Voyager announces first participants dosed in Phase 1 SAD trial of VY-TAU01
- Voyager Therapeutics price target lowered to $8 from $10 at Wedbush
- Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results